

Memo

To: AML Reference Laboratory Clients

From: Allina Medical Laboratories, Reference Laboratory Services

Date: May 12, 2006

Re: Antimicrobial Susceptibility Panel Changes

Due to the FDA alert on the contraindication for gatifloxacin in diabetic patients, the Allina Infectious Disease Task Force, with representation from all metro and regional hospitals, made the decision to remove gatifloxacin from the formularies. The new preferred quinolone contract will be a combination of moxifloxacin and ciprofloxacin.

Effective immediately, the antimicrobial susceptibility batteries have been revised to conform to this change. Please see the additional attachment for the updated susceptibility panels.